BioSpace News Archive

Immunexpress, Pty Ltd. today announced that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress in Phoenix, Arizona, January 21 to 23, 2024.

ImmunoBrain Checkpoint Inc. today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Aclarion, Inc. announced that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.

Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination.

Curasight A/S announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight’s uTRACE® PET imaging technology for the improved diagnosis of prostate cancer.

Galderma announced it has received approval from Health Canada for Restylane® SHAYPE™, a hyaluronic acid injectable designed for temporary augmentation of the chin region.2 Engineered to build and shape on bone with deep injection for a bone-mimicking effect,1,2,3,4† Restylane® SHAYPE™ will be available in Canada as of February 2024.

ANGLE plc is pleased to announce the publication of a peer-reviewed paper in a special issue of the journal - “Current Issues in Molecular Biology” Special Issue: Advanced Solutions for Cancer Therapy.

Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.

Abivax SA, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, provides an outlook on its 2024 strategic priorities and milestones.